Amber Tong is a Senior Editor for Endpoints News, a leading publication covering the biopharmaceutical industry. With a focus on life sciences, Amber's work includes in-depth articles on drug development, clinical trials, biotech financing, and industry trends. Her expertise and contributions have also been featured in NXTmine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Amber's coverage mainly focuses on healthcare and pharmaceuticals, with a significant emphasis on company announcements and clinical trial outcomes. She appears to be particularly interested in developments within the pharmaceutical industry, including drug development, clinical trials, and company acquisitions.
Given her focus on private sector announcements and press releases, Amber may be more responsive to pitches related to exclusive news from within the pharmaceutical industry or expert insights into major developments such as clinical trial results or company strategies.
It is important to note that Amber does not seem to have a specific geographic focus but rather provides comprehensive coverage of global pharmaceutical industry developments.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Amber Tong
Bristol Myers Squibb has backed out of a TIGIT partnership with Agenus, returning a bispecific that it had paid $200 million upfront to license. …
By: Amber Tong
Bayer is “on track” to realize the €2 billion in cost savings it's aiming for in 2026, executives say, even as they report another quarter …
By: Amber Tong
Just months after Entero Therapeutics completed the merger that brought in its new lead candidate, the debt inherited from the deal is creeping up on …
By: Amber Tong
Welcome back to Endpoints Weekly, your review of the week's top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …
By: Amber Tong, Gene Tx
More than a year after launching the first-ever gene therapy for hemophilia B, CSL Behring revealed that it's treated more than 12 patients so far …
By: Amber Tong
Two of AstraZeneca's top cancer treatments have been approved in combination to treat a subgroup of endometrial cancer patients in the European Union, the drugmaker …
By: Amber Tong
As next-generation contenders in the obesity treatment space communicate plans to speed up their drug programs, Zealand Pharma appears to have gotten the memo. …
By: Amber Tong
The FDA on Thursday lifted a partial clinical hold on an early-stage study of a HER3-targeting antibody-drug conjugate that BioNTech is developing with China-based MediLink …
By: Max Gelman, Amber Tong
Welcome back to Endpoints Weekly, your review of the week's top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …
By: Amber Tong
BioMarin's decision to scale back its gene therapy ambitions will result in about 225 employees losing their jobs, the biotech disclosed late Wednesday.
(833) 317-6278 
